Lack of association of OPRM1 genotype and smoking cessation.
<p>INTRODUCTION: Previous studies have reported an association between μ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2013
|
| _version_ | 1797070202985250816 |
|---|---|
| author | Munafò, MR Johnstone, E Aveyard, P Marteau, T |
| author2 | Society for Research on Nicotine and Tobacco |
| author_facet | Society for Research on Nicotine and Tobacco Munafò, MR Johnstone, E Aveyard, P Marteau, T |
| author_sort | Munafò, MR |
| collection | OXFORD |
| description | <p>INTRODUCTION: Previous studies have reported an association between μ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism in the OPRM1 gene is associated with cessation and whether this variant moderates the effects of higher doses of NRT on abstinence.</p><p>METHODS: Participants were recruited from the practices of primary care physicians in the United Kingdom. Patients smoking an average of at least 10 cigarettes a day, who wanted to quit and were 18 years or older were eligible for inclusion. A total of N = 633 participants were recruited into the original trial, of whom complete data for pharmacogenetic analyses were available on n = 598. Logistic regression was used to test for the effects of OPRM1 genotype and NRT dose, including the genotype × dose interaction term, on smoking status at 4-week, and 26-week follow-up. Analyses were adjusted for potential confounders.</p><p>RESULTS: There was no evidence of a genotype effect at either follow-up, and no evidence of a genotype × dose interaction effect. CONCLUSIONS: OPRM1 genotype may not affect the likelihood of smoking cessation, and it may not influence response to high- versus low-dose NRT. OPRM1 may have at most only a modest role in explaining cigarette smoking and cessation.</p> |
| first_indexed | 2024-03-06T22:35:32Z |
| format | Journal article |
| id | oxford-uuid:59c1324e-bcce-4de8-82b7-e98aa9e83b5d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:35:32Z |
| publishDate | 2013 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:59c1324e-bcce-4de8-82b7-e98aa9e83b5d2022-03-26T17:11:42ZLack of association of OPRM1 genotype and smoking cessation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:59c1324e-bcce-4de8-82b7-e98aa9e83b5dEnglishSymplectic Elements at OxfordOxford University Press2013Munafò, MRJohnstone, EAveyard, PMarteau, TSociety for Research on Nicotine and Tobacco<p>INTRODUCTION: Previous studies have reported an association between μ-opioid receptor (OPRM1) genotype and smoking cessation, with some evidence that the strength of this association depends on dose of nicotine replacement therapy (NRT). We examined whether a single-nucleotide polymorphism in the OPRM1 gene is associated with cessation and whether this variant moderates the effects of higher doses of NRT on abstinence.</p><p>METHODS: Participants were recruited from the practices of primary care physicians in the United Kingdom. Patients smoking an average of at least 10 cigarettes a day, who wanted to quit and were 18 years or older were eligible for inclusion. A total of N = 633 participants were recruited into the original trial, of whom complete data for pharmacogenetic analyses were available on n = 598. Logistic regression was used to test for the effects of OPRM1 genotype and NRT dose, including the genotype × dose interaction term, on smoking status at 4-week, and 26-week follow-up. Analyses were adjusted for potential confounders.</p><p>RESULTS: There was no evidence of a genotype effect at either follow-up, and no evidence of a genotype × dose interaction effect. CONCLUSIONS: OPRM1 genotype may not affect the likelihood of smoking cessation, and it may not influence response to high- versus low-dose NRT. OPRM1 may have at most only a modest role in explaining cigarette smoking and cessation.</p> |
| spellingShingle | Munafò, MR Johnstone, E Aveyard, P Marteau, T Lack of association of OPRM1 genotype and smoking cessation. |
| title | Lack of association of OPRM1 genotype and smoking cessation. |
| title_full | Lack of association of OPRM1 genotype and smoking cessation. |
| title_fullStr | Lack of association of OPRM1 genotype and smoking cessation. |
| title_full_unstemmed | Lack of association of OPRM1 genotype and smoking cessation. |
| title_short | Lack of association of OPRM1 genotype and smoking cessation. |
| title_sort | lack of association of oprm1 genotype and smoking cessation |
| work_keys_str_mv | AT munafomr lackofassociationofoprm1genotypeandsmokingcessation AT johnstonee lackofassociationofoprm1genotypeandsmokingcessation AT aveyardp lackofassociationofoprm1genotypeandsmokingcessation AT marteaut lackofassociationofoprm1genotypeandsmokingcessation |